ChemMedChem · 2015 · 11 citations · 48 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAnti-inflammatory PharmacologyLigand BindingMolecular DockingMolecular ModelingProtein-ligand DockingStructure-activity Relationship AnalysisAnticancer ActivityDocking-based Drug DesignMedicinal Chemistry ApplicationsMolecular Docking Of InhibitorsNuclear Factor Kappa B ActivationNuclear Factor Kappa B SignalingProtein Kinase InhibitorsStructure-activity Relationship Modeling
Inhibitor of nuclear factor κB kinase 2 (IKK2) is suggested to be a potential target for the development of novel anti-inflammatory and anticancer drugs. In this work, we applied structure-based drug design to improve the potency of the inhibitor (E)-N'-(4-nitrobenzylidene)-2-naphthohydrazide (LASSBio-1524, 1 a: IC50 =20 μm). The molecular model built for IKK2 together with the docking methodology employed were able to provide important and consistent information with respect to the structural and chemical inhibitor characteristics that may confer potency to IKK2 inhibitors, providing important guidelines for the development of a new N-acylhydrazone (NAH) derivative. (E)-N'-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzylidene)-2-naphthohydrazide hydrochloride (LASSBio-1829 hydrochloride, 10) is a 7-azaindole NAH able to inhibit IKK2 with an IC50 value of 3.8 μm. LASSBio-1829 hydrochloride was found to be active in several pharmacological inflammation tests in vivo, showing its potential as an anti-inflammatory prototype.
48
Basic local alignment search tool
Stephen F. Altschul, Warren Gish, Webb Miller et al. · Journal of Molecular Biology · 1990 · 94.5K citations
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids
Laura C. Green, David A. Wagner, Joseph A. Glogowski et al. · Analytical Biochemistry · 1982 · 12.1K citations